379 related articles for article (PubMed ID: 12414537)
1. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
[TBL] [Abstract][Full Text] [Related]
3. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
Fox WD; Higgins B; Maiese KM; Drobnjak M; Cordon-Cardo C; Scher HI; Agus DB
Clin Cancer Res; 2002 Oct; 8(10):3226-31. PubMed ID: 12374693
[TBL] [Abstract][Full Text] [Related]
4. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization.
Mesiano S; Ferrara N; Jaffe RB
Am J Pathol; 1998 Oct; 153(4):1249-56. PubMed ID: 9777956
[TBL] [Abstract][Full Text] [Related]
5. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.
Bauer AJ; Terrell R; Doniparthi NK; Patel A; Tuttle RM; Saji M; Ringel MD; Francis GL
Thyroid; 2002 Nov; 12(11):953-61. PubMed ID: 12490072
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
Inoue K; Slaton JW; Perrotte P; Davis DW; Bruns CJ; Hicklin DJ; McConkey DJ; Sweeney P; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Dec; 6(12):4874-84. PubMed ID: 11156247
[TBL] [Abstract][Full Text] [Related]
8. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
[TBL] [Abstract][Full Text] [Related]
9. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.
Yukita A; Asano M; Okamoto T; Mizutani S; Suzuki H
Anticancer Res; 2000; 20(1A):155-60. PubMed ID: 10769648
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
[TBL] [Abstract][Full Text] [Related]
11. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of intraperitoneal albendazole and paclitaxel on ascites formation and expression of vascular endothelial growth factor in ovarian cancer cell-bearing athymic nude mice.
Choi EK; Kim SW; Nam EJ; Paek J; Yim GW; Kang MH; Kim YT
Reprod Sci; 2011 Aug; 18(8):763-71. PubMed ID: 21421899
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor.
Gossmann A; Helbich TH; Mesiano S; Shames DM; Wendland MF; Roberts TP; Ferrara N; Jaffe RB; Brasch RC
Am J Obstet Gynecol; 2000 Oct; 183(4):956-63. PubMed ID: 11035346
[TBL] [Abstract][Full Text] [Related]
14. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
Borgström P; Gold DP; Hillan KJ; Ferrara N
Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376
[TBL] [Abstract][Full Text] [Related]
15. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma.
Dagnaes-Hansen F; Rasmussen LM; Tilton R; Denner L; Flyvbjerg A
Anticancer Res; 2003; 23(2B):1625-30. PubMed ID: 12820432
[TBL] [Abstract][Full Text] [Related]
16. Bikunin plus paclitaxel markedly reduces tumor burden and ascites in mouse model of ovarian cancer.
Kobayashi H; Yagyu T; Inagaki K; Kondo T; Suzuki M; Kanayama N; Terao T
Int J Cancer; 2004 May; 110(1):134-9. PubMed ID: 15054878
[TBL] [Abstract][Full Text] [Related]
17. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
Belotti D; Paganoni P; Manenti L; Garofalo A; Marchini S; Taraboletti G; Giavazzi R
Cancer Res; 2003 Sep; 63(17):5224-9. PubMed ID: 14500349
[TBL] [Abstract][Full Text] [Related]
20. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
Tedjarati S; Baker CH; Apte S; Huang S; Wolf JK; Killion JJ; Fidler IJ
Clin Cancer Res; 2002 Jul; 8(7):2413-22. PubMed ID: 12114447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
